BioMaxima increased net profit by 400%.

2022-09-30 18:46

2022-09-30 18:46

BioMaxima increased net profit by 400%.
BioMaxima increased net profit by 400%.
/ Biomaxima

BioMaxima increased its net revenues in the first half of this year. by 283 percent y / y, and net profit by 400 percent. – the BioMaxima Capital Group announced on Friday. It was reported that the record results were influenced, among others, by contract for the supply of tests for SARS-Cov-2 diagnostics with a public finance unit.

According to the published report, the consolidated net revenues of the company listed on the WSE in the first half of 2022 amounted to PLN 117.47 million (an increase by 283% y / y), while the net profit amounted to PLN 27.64 million, after an increase by 400 proc y / y

It was written that the record results were influenced, among others, by a contract with a public finance unit for the supply of SARS-Cov-2 diagnostic tests worth PLN 94.8 million, implemented from January to April. BioMaxima also recorded a jump in sales of disc diffusion systems for drug sensitivity testing (antibiograms) in the first half of 2022, at the level of 275%. Every year.

It was noted that the company is the only producer of this assortment in Poland and one of the few in the world. The issuer announced that as at the publication date of the report, monthly orders totaled 400 thousand. PLN and contributing to revenues and profitability, they will partially replace the range related to SARS-CoV-2 in the following quarters.

It was indicated that, in line with the implemented business model, BioMaxima adapts its diagnostic platforms in order to meet the current needs of health care services related to infectious diseases on an ongoing basis. In the first half of 2022, e.g. two new products: monkey pox virus detection tests. The MPXV Real Time PCR LAB-KIT ™ genetic diagnostic test and the Monkeypox Ag Rapid rapid antigen test are available in the company’s constantly growing distribution network in the European Union.

“In the first half of 2022, we consistently implemented our strategy of offer development and expansion of the distribution network. The stable financial and organizational situation allowed us to focus on intensifying marketing activities, both in Poland and on foreign markets. after the COVID-19 pandemic, the interest of potential recipients in our offer allows us to assume that the second half of 2022 will also bring many reasons for satisfaction “- summarized the president of the company Łukasz Urban, quoted in the information.

In the first half of 2022, the company started construction works related to a new production plant with warehouse and office space, which will take up 2,350 sq m. The commissioning is scheduled for the second quarter of 2023.

The company also announced that it had completed the buy-back of its own shares since June. The share buyback program was completed as all the allocated funds were used up. The company concluded transactions of purchase of 180,187 own shares, constituting 4.163% of the total. capital, entitling to 180,187 votes at the General Meeting. (PAP)

ewes / pad /


Related Articles

Back to top button